AxoGen, Inc. (NASDAQ:AXGN - Get Free Report) Director Amy Mcbride Wendell sold 5,000 shares of the company's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $20.02, for a total transaction of $100,100.00. Following the completion of the transaction, the director now owns 97,899 shares of the company's stock, valued at $1,959,937.98. This trade represents a 4.86 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
AxoGen Stock Performance
Shares of NASDAQ:AXGN opened at $18.21 on Thursday. The company has a market cap of $807.50 million, a price-to-earnings ratio of -56.91 and a beta of 1.00. The company has a 50-day moving average price of $17.84 and a 200-day moving average price of $15.22. The company has a current ratio of 3.74, a quick ratio of 2.47 and a debt-to-equity ratio of 0.67. AxoGen, Inc. has a 12 month low of $5.55 and a 12 month high of $21.00.
Hedge Funds Weigh In On AxoGen
Several hedge funds and other institutional investors have recently modified their holdings of the company. Driehaus Capital Management LLC raised its stake in AxoGen by 166.0% in the fourth quarter. Driehaus Capital Management LLC now owns 954,439 shares of the medical equipment provider's stock worth $15,729,000 after buying an additional 595,579 shares in the last quarter. JPMorgan Chase & Co. raised its stake in AxoGen by 2,912.3% in the third quarter. JPMorgan Chase & Co. now owns 549,000 shares of the medical equipment provider's stock worth $7,697,000 after buying an additional 530,775 shares in the last quarter. First Light Asset Management LLC raised its stake in AxoGen by 10.2% in the fourth quarter. First Light Asset Management LLC now owns 4,506,795 shares of the medical equipment provider's stock worth $74,272,000 after buying an additional 416,499 shares in the last quarter. Parkman Healthcare Partners LLC bought a new position in AxoGen in the third quarter worth about $5,789,000. Finally, Balyasny Asset Management L.P. bought a new position in AxoGen in the fourth quarter worth about $4,943,000. 80.29% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
Several analysts have issued reports on the stock. Canaccord Genuity Group upped their price target on shares of AxoGen from $22.00 to $26.00 and gave the company a "buy" rating in a research report on Wednesday, February 26th. Cantor Fitzgerald restated an "overweight" rating and set a $24.00 price target on shares of AxoGen in a research report on Wednesday. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, AxoGen has a consensus rating of "Buy" and an average target price of $20.75.
Check Out Our Latest Research Report on AXGN
About AxoGen
(
Get Free Report)
AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
